FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094345617> ?p ?o ?g. }

• W2094345617 endingPage "64" @default.
• W2094345617 startingPage "64" @default.
• W2094345617 abstract "Osteoarthritis (OA) is often treated with nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or specific inhibitors of cyclooxygenase 2 (COX-2).To assess the relative therapeutic efficacy of rofecoxib, celecoxib, and acetaminophen in adults with OA.Randomized, parallel-group, double-blind trial, conducted from June 1999 to February 2000, in 29 clinical centers in the United States.Three hundred eighty-two patients aged at least 40 years who had OA of the knee that was previously treated with NSAIDs or acetaminophen.Patients were randomly assigned to receive rofecoxib, 12.5 mg/d (n = 96); rofecoxib, 25 mg/d (n = 95); celecoxib, 200 mg/d (n = 97); or acetaminophen, 4000 mg/d (n = 94) for 6 weeks.Assessments over days 1 to 6 and over 6 weeks included pain on walking, night pain, pain at rest, and morning stiffness as measured on a Western Ontario McMaster Universities Osteoarthritis Index (100-mm visual analog scale [VAS]) and global response to therapy compared among 4 treatment groups.79% of patients completed the study. More patients treated with acetaminophen discontinued early due to lack of efficacy than patients treated with COX-2 inhibitors (31% vs 18%-19%). Efficacy assessed in the first 6 days of therapy showed greatest response to rofecoxib, 25 mg/d, followed by rofecoxib, 12.5 mg/d, celecoxib, and acetaminophen, respectively, in terms of relief of pain on walking (-32.2, - 29.0, - 26.4, and -20.6 mm change on the VAS; P</=.04 for all others vs acetaminophen; P =.05 for 25-mg rofecoxib vs celecoxib), rest pain (-21.8, - 18.6, - 15.5, and - 12.5 mm; P</=.02 for either dose of rofecoxib vs acetaminophen and P =.02 for rofecoxib, 25 mg/d, vs celecoxib), night pain (-25.2, - 22.0, - 18.7, and - 18.8 mm; P =.04 for rofecoxib, 25 mg/d, vs both acetaminophen and celecoxib), and morning stiffness (-30.4, - 28.4, - 25.7, and - 20.9 mm; P</=.02 for either dose of rofecoxib vs acetaminophen). Over 6 weeks, rofecoxib, 25 mg/d, provided greatest response for night pain (P<.002 vs celecoxib and P =.006 vs acetaminophen and P =.02 vs rofecoxib, 12.5 mg/d), composite pain subscale (P</=.03 vs all other treatments), stiffness subscale (P</=.04 vs celecoxib and acetaminophen), and physical function subscale (P =.001 vs acetaminophen). Global responses over 6 weeks showed a similar pattern (good or excellent response at week 6: 60%, 56%, 46%, and 39%, respectively; P</=.03 for rofecoxib, 25 mg/d, vs celecoxib and acetaminophen; P =.02 for rofecoxib, 12.5 mg/d, vs acetaminophen). All treatments were generally safe and well tolerated.Rofecoxib, 25 mg/d, provided efficacy advantages over acetaminophen, 4000 mg/d, celecoxib, 200 mg/d, and rofecoxib, 12.5 mg, for symptomatic knee OA." @default.
• W2094345617 created "2016-06-24" @default.
• W2094345617 creator A5013937306 @default.
• W2094345617 creator A5023716582 @default.
• W2094345617 creator A5030644838 @default.
• W2094345617 creator A5052221041 @default.
• W2094345617 creator A5059837134 @default.
• W2094345617 creator A5064599465 @default.
• W2094345617 date "2002-01-02" @default.
• W2094345617 modified "2023-09-25" @default.
• W2094345617 title "Efficacy of Rofecoxib, Celecoxib, and Acetaminophen in Osteoarthritis of the Knee" @default.
• W2094345617 cites W127956218 @default.
• W2094345617 cites W1536681507 @default.
• W2094345617 cites W1587059515 @default.
• W2094345617 cites W1587123510 @default.
• W2094345617 cites W1983104516 @default.
• W2094345617 cites W2009962040 @default.
• W2094345617 cites W2012810767 @default.
• W2094345617 cites W2044750065 @default.
• W2094345617 cites W205202163 @default.
• W2094345617 cites W2058147305 @default.
• W2094345617 cites W2058834020 @default.
• W2094345617 cites W2076605758 @default.
• W2094345617 cites W2076657068 @default.
• W2094345617 cites W2081734937 @default.
• W2094345617 cites W2123366546 @default.
• W2094345617 cites W2130674238 @default.
• W2094345617 cites W2163756514 @default.
• W2094345617 cites W2332196493 @default.
• W2094345617 cites W75297534 @default.
• W2094345617 cites W2983297087 @default.
• W2094345617 doi "https://doi.org/10.1001/jama.287.1.64" @default.
• W2094345617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11754710" @default.
• W2094345617 hasPublicationYear "2002" @default.
• W2094345617 type Work @default.
• W2094345617 sameAs 2094345617 @default.
• W2094345617 citedByCount "223" @default.
• W2094345617 countsByYear W20943456172012 @default.
• W2094345617 countsByYear W20943456172013 @default.
• W2094345617 countsByYear W20943456172014 @default.
• W2094345617 countsByYear W20943456172015 @default.
• W2094345617 countsByYear W20943456172016 @default.
• W2094345617 countsByYear W20943456172017 @default.
• W2094345617 countsByYear W20943456172018 @default.
• W2094345617 countsByYear W20943456172019 @default.
• W2094345617 countsByYear W20943456172020 @default.
• W2094345617 countsByYear W20943456172021 @default.
• W2094345617 countsByYear W20943456172022 @default.
• W2094345617 countsByYear W20943456172023 @default.
• W2094345617 crossrefType "journal-article" @default.
• W2094345617 hasAuthorship W2094345617A5013937306 @default.
• W2094345617 hasAuthorship W2094345617A5023716582 @default.
• W2094345617 hasAuthorship W2094345617A5030644838 @default.
• W2094345617 hasAuthorship W2094345617A5052221041 @default.
• W2094345617 hasAuthorship W2094345617A5059837134 @default.
• W2094345617 hasAuthorship W2094345617A5064599465 @default.
• W2094345617 hasBestOaLocation W20943456171 @default.
• W2094345617 hasConcept C126322002 @default.
• W2094345617 hasConcept C14184104 @default.
• W2094345617 hasConcept C142724271 @default.
• W2094345617 hasConcept C181199279 @default.
• W2094345617 hasConcept C185592680 @default.
• W2094345617 hasConcept C204787440 @default.
• W2094345617 hasConcept C2776164576 @default.
• W2094345617 hasConcept C2776467144 @default.
• W2094345617 hasConcept C2778582115 @default.
• W2094345617 hasConcept C2778722691 @default.
• W2094345617 hasConcept C2779689624 @default.
• W2094345617 hasConcept C42219234 @default.
• W2094345617 hasConcept C55493867 @default.
• W2094345617 hasConcept C71924100 @default.
• W2094345617 hasConceptScore W2094345617C126322002 @default.
• W2094345617 hasConceptScore W2094345617C14184104 @default.
• W2094345617 hasConceptScore W2094345617C142724271 @default.
• W2094345617 hasConceptScore W2094345617C181199279 @default.
• W2094345617 hasConceptScore W2094345617C185592680 @default.
• W2094345617 hasConceptScore W2094345617C204787440 @default.
• W2094345617 hasConceptScore W2094345617C2776164576 @default.
• W2094345617 hasConceptScore W2094345617C2776467144 @default.
• W2094345617 hasConceptScore W2094345617C2778582115 @default.
• W2094345617 hasConceptScore W2094345617C2778722691 @default.
• W2094345617 hasConceptScore W2094345617C2779689624 @default.
• W2094345617 hasConceptScore W2094345617C42219234 @default.
• W2094345617 hasConceptScore W2094345617C55493867 @default.
• W2094345617 hasConceptScore W2094345617C71924100 @default.
• W2094345617 hasIssue "1" @default.
• W2094345617 hasLocation W20943456171 @default.
• W2094345617 hasLocation W20943456172 @default.
• W2094345617 hasOpenAccess W2094345617 @default.
• W2094345617 hasPrimaryLocation W20943456171 @default.
• W2094345617 hasRelatedWork W1595623816 @default.
• W2094345617 hasRelatedWork W1820127304 @default.
• W2094345617 hasRelatedWork W192576539 @default.
• W2094345617 hasRelatedWork W2011327495 @default.
• W2094345617 hasRelatedWork W2034257523 @default.
• W2094345617 hasRelatedWork W2094345617 @default.
• W2094345617 hasRelatedWork W2361206304 @default.
• W2094345617 hasRelatedWork W2393019286 @default.

• next